Daubert v. Merrell Dow Pharmaceuticals, Inc.

From Conservapedia
This is the current revision of Daubert v. Merrell Dow Pharmaceuticals, Inc. as edited by Aschlafly (Talk | contribs) at 02:48, August 23, 2020. This URL is a permanent link to this version of this page.

(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to: navigation, search

In Daubert v. Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579, 113 S. Ct. 2786 (1993), the U.S. Supreme Court established minimum standards for the admissibility of expert testimony in court. These requirements included testability and falsifiability.

Federal Rule of Evidence 702 has been revised since Daubert was decided in 1993, and "[a]t this point, Rule 702 has superseded Daubert, but the standard of review that was established for Daubert challenges is still appropriate." United States v. Parra, 402 F.3d 752, 758 (7th Cir. 2005).